Sai Parenteral's Q1 FY27 Earnings Call — Analysis (NSE: SAIPARENT)

Sai Parenterals pivots IPO funds to acquire injectable and R&D assets, signs AUD 202M Australian pharmacy contract renewal, and reiterates FY27 revenue and margin guidance.

18 Aug 2026 · Analysis by Alpha Inflection

Result quality: watch — Margin pressure. Management sentiment: optimistic.

The take

Q1FY27 Consolidated Revenue ₹182 Cr ( -₹19 Cr QoQ ) . New guidance — FY27 fy27 consolidated revenue ₹750 Cr . New story: Regulatory-forced capacity redeployment .

Results

Consolidated revenue ₹182 Cr (down QoQ from ₹201 Cr), gross margin 41.8% (+370 bps QoQ), EBITDA margin 14.9% (+50 bps QoQ), PAT ₹8 Cr; standalone revenue grew 175% YoY to ₹56 Cr.

Financial highlights

Guidance

FY27 consolidated revenue guided at ₹750 Cr with ~17% EBITDA margin, H2-weighted 45:55; peak debt expected in FY27 followed by deleveraging from FY28.

What management committed to

• Consolidated revenue for FY27 will be ₹750 crore. — ₹750 Cr, FY27
• Consolidated EBITDA margin for FY27 will be around 17%. — ~17%, FY27
• Full benefit of raw material cost recovery will flow across the contract book by the end of Q2FY27, further improving gross margins. — Q2FY27
• The Saicriti Pharma injectable facility will be completed by April 2027 with capacity of approximately 154.66 million units per annum. — 154.66 million units, Q4FY27
• The acquisition of 60% stake in Prathyak Laboratories will be completed on or before 30 September 2026. — Q2FY27
• The Adelaide manufacturing facility will achieve physical completion by January 2027, TGA licensing inspection by 31 March 2027, and start Phase 1 manufacturing in April 2027. — Q4FY27
• The renewed EBOS Group supply agreement will generate approximately AUD 27 million in base annual revenue for 7.5 years starting Q2FY27, with 12 new products added every year that will provide incremental revenue above the base AUD 202 million contract value. — AUD 27 million per year; AUD 202 million total base; 12 new products/year, FY34
• Consolidated debt will peak in FY27 and then begin to deleverage from FY28 with gross debt-to-equity ratio around 0.6x at peak. — D/E ~0.6x, FY28

Key themes

IPO fund redeployment, pharmacy contract renewal, and margin recovery

How the narrative shifted

• Regulatory-forced capacity redeployment: Management is recasting the IPO capex plan as a necessary and value-accretive response to Telangana’s HILTP policy that blocks upgradation inside the outer ring road, framing the Saicriti acquisition as a faster, higher-capacity, and regulatory-compliant alternative.
• Long-term pharmacy contract lock-in: The renewal of the EBOS contract for 7.5 years with AUD 202M base value and annual NPD additions is presented as a foundation for predictable, growing recurring revenue that justifies capacity investments.
• Australian vertical integration on track: The Adelaide facility is portrayed as paramount for sovereignty and supply security, converting Noumed from a third-party sourcing model to a self-manufacturing, IP-holding platform with reduced inventory and working capital.
• Gross margin recovery via input cost pass-through: The lagged pass-through of raw material cost increases is unwinding, evidenced by the 370 bps QoQ gross margin expansion; full benefit is expected in Q2, reinforcing confidence in the 17% EBITDA margin target.
• Execution bandwidth through decentralised teams: Faced with concerns about managing multiple simultaneous initiatives, management emphasises that each acquisition retains its operational leadership with skin in the game, reducing the burden on Sai’s central management.
• Peak debt and deleveraging pathway: Management assures that FY27 is the peak debt year, with gross D/E a comfortable 0.6x, and that deleveraging will naturally begin in FY28 as new assets start contributing to cash flows.

Operational commentary

• Board approved variation in IPO objects to acquire 60% stake in Saicriti Pharma (under-construction EU-GMP/USFDA injectable facility, 154.66 Mn units, completion Apr 2027) with ₹83.83 Cr and 60% in Prathyak Laboratories (R&D platform, 150 SKUs, 86 molecules, completion by 30 Sep 2026) with ₹15 Cr.
• Noumed renewed exclusive supply agreement with EBOS Group (TerryWhite Chemmart, Pharmacy Choice) at AUD 202M (~₹1,300 Cr) for 7.5 years from Q2FY27, with annual addition of 12 new products on top of the base value.
• Adelaide facility on schedule: physical completion Jan 2027, TGA inspection Mar 2027, Phase 1 manufacturing Apr 2027; full AUD 53M funding completed.
• Consolidated gross margin expanded 370 bps QoQ to 41.8% as raw material cost recoveries flowed through contract book; lag of 90–120 days unwinding in company's favour.
• West Asia supply-chain disruption caused air freight costs at Noumed impacting Q1 margins; service levels and minimum supply obligations fully met; disruption expected to normalise.
• Board approved incorporation of US subsidiary through Singapore step-down to evaluate US market entry; evaluation at preliminary stage.
• Standalone business delivered 175% YoY revenue growth with EBITDA margin expanding 890 bps to 29% on operating leverage.

Analyst Q&A

• Q. Does the AUD 202M contract value include the 12 new drugs per year or are they incremental?

  The 12 products are above the existing base value; the AUD 202M reflects the existing supply portfolio value, and new products add incremental revenue.

• Q. With multiple initiatives (Noumed, Saicriti, Prathyak, US entry), how is management bandwidth being preserved?

  Sai invests in management teams at each acquisition—Noumed is led by Mark and his team with 25.4% ownership; Prathyak has 67 personnel with experienced leaders retained; bandwidth is decentralised, not dependent solely on Sai’s management.

• Q. Is there any thought process on an upward revision of guidance for FY28?

  We have not thought about FY28 yet; we want to see the next 2-3 quarters before committing to a number. We will revisit before the last quarter.

• Q. What is the precise US subsidiary strategy—sales, manufacturing, and when will it contribute meaningfully?

  It is too premature to discuss; the subsidiary is being formed only to validate opportunities, and we will disclose when evaluation is completed.

View source

Research and educational content only. Not investment advice.